The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about the study, please email email@example.com or call 312-355-5112.
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IV A, Stage IV B or Recurrent Endometrial Cancer
Sponsor: National Cancer Institute
Principal Investigator: Oana Danciu, MD